Preventing relapse before stem cell transplant
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new approach to reduce the chance of leukemia or other blood cancers coming back after a stem cell transplant. It uses careful monitoring before the transplant to try to prevent relapse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older at the time of the transplant.
- You must have a type of blood cancer such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or myeloproliferative neoplasm (MPN).
- Before the transplant, your disease must be measurable, meaning tests like flow cytometry, genetic sequencing (NGS), or PCR show signs of the cancer.
- You must be able to understand and sign the informed consent document.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a precise type of radiation called intensity modulated total marrow irradiation before a stem cell transplant. It aims to destroy cancer cells while reducing side effects for patients with high-risk leukemia or myelodysplastic syndrome.
This study tests whether a medication called IFN-α can help prevent the blood cancer from coming back after a stem cell transplant. It is for people with certain types of blood cancers who are at high risk of relapse.
This trial tests a new treatment called NCR300 to see if it can prevent acute myeloid leukemia (AML) from coming back after a stem cell transplant. It may help people who are at high risk of relapse.
This trial tests whether taking two drugs, ruxolitinib and azacitidine, after a reduced-intensity stem cell transplant can help prevent acute myeloid leukemia (AML) from returning. It is for patients who are in remission and at high risk of relapse.
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
This trial tests whether giving donor natural killer (NK) cells after a stem cell transplant can help prevent leukemia from coming back. It is for people aged 14-25 with certain hard-to-treat leukemias who are already getting a stem cell transplant from a related donor.
Hear when a new Myelodysplastic Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.